Healthcare · NSE/BSE: MANKIND
Mankind Pharma Limited
Pharmaceuticals
Market Cap ₹0.97L Cr
Verdict: Average
Quality Scores
Multi-Bagger
78/100
Compounder Quality
82/100
Management Credibility
85/100
Governance
92/100
Cash Flow Quality
88/100
AI Summary
Mankind Pharma is a dominant player in the Indian Pharmaceutical Market (IPM), ranking #1 in prescriptions and #2 by volume. The company has demonstrated robust growth with a 5-year sales CAGR of 18%, transitioning from a purely acute player to a diversified healthcare powerhouse with strong consumer brands like Manforce and Prega News. Historically debt-free, the company undertook a massive spike in borrowings (to ₹8,511 Cr in FY25) likely to fund the landmark acquisition of BSV. While its operational execution is elite, and market positioning is superior, the recent balance sheet expansion…
Top Opportunities
- Consistent double digit revenue growth
- Negative working capital cycle achieved in 2025
- Strong OCF generation above 2000 Cr
Top Risks
- Significant increase in debt for acquisitions
- Inventory days remain high (180+ days)
- Decreasing promoter holding over last 3 years
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.